INCY Incyte Corporation
Company Analysis
Latest News
🟢 Incyte is trading 4.09% up in after-hours trading amid broadly positive U.S. equity sentiment
Incyte is trading at $134.10, +4.09% in after-hours trading amid broadly positive U.S. equity sentiment. - This follows September 2, 2026’s regular-session...
Incyte Enters Pricing Agreement with CMS for Jakafi in State Medicaid Programs
Incyte Corporation has entered into an agreement with the U.S. Centers for Medicare & Medicaid Services (CMS) to align the pricing of its drugs Jakafi and...
Incyte Secures $337 Million from Major Funds, Citing Positive Cancer Data
Incyte Corporation attracted significant institutional investment according to filings released on August 27, 2026. These second-quarter transactions reflect...
🟢 Incyte rises 4.0% — Biotech Sector Surges on Positive mRNA Cancer Vaccine Trial Results
With Biotech (XBI) up 3.7%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, proxied by the XBI ETF, is trading...
🔴 Incyte is trading 4.2% down today on profit-taking after post-earnings surge
Incyte is trading 4.2% down at $121.81 as the stock undergoes a period of normalization and profit-taking following a sharp two-day rally. • The stock...
🔴 Incyte is trading 7.6% down today following its Q2 earnings release and guidance update
Incyte is trading at $120.00, down 7.6% in after-hours trading following its second-quarter 2026 earnings release and updated guidance. • While revenue and...
Incyte Crushes Q2 Estimates on a $246 Million Accounting Windfall — But Can Investors Count on This Growth Rate Sticking?
Shares surged +10.6% to $131.46 after Incyte delivered a second quarter that blew past Wall Street on almost every metric. But the headline numbers carry a...
🟢 Incyte is trading 10.59% up today on Q2 earnings beat and raised guidance
Incyte is trading at $131.46 (+10.59%) after second-quarter results beat estimates and management raised full-year guidance. • The company reported $1.67...
🟢 Incyte is trading 4.6% up today after a strong Q2 earnings beat and raised guidance
Incyte is trading 4.6% up today at $125.32 after reporting a strong second-quarter earnings beat and raising its full-year guidance. • The rally is primarily...
Incyte's second quarter revenue and EPS significantly beat estimates, driven by a one-time Opzelura benefit, leading to raised full-year guidance.
Incyte reported second quarter 2026 revenue of $1.67 billion, up 38% year-over-year, and non-GAAP diluted EPS of $3.09. These results significantly surpassed...
Incyte Corporation Q2 2026 Earnings Preview: What Analysts Expect on July 28, 2026
For the second quarter of 2026, analysts anticipate Incyte to report consensus revenue of $1.40 billion and an adjusted EPS of $1.61, while the stock currently...
Incyte and Halozyme Announce Collaboration for Subcutaneous Cancer Drug Formulation
Incyte Corporation and Halozyme Therapeutics formed a global collaboration and license agreement. They will develop a subcutaneous formulation for Incyte's...
Incyte's Latarcibart Shows 81% Reduction in Bleeding Rate in Phase 1/2 VWD Study
Incyte announced positive results from its Phase 1/2 study of latarcibart for Von Willebrand Disease (VWD). The company presented this data at the ISTH 2026...
Incyte completes acquisition of Vega Therapeutics for $1.25B upfront payment
Incyte Corporation has completed its previously announced acquisition of Vega Therapeutics, Inc., a subsidiary of Star Therapeutics, to expand its hematology...
Incyte's Opzelura wins EU backing, set to be first steroid-free JAK inhibitor
Incyte announced on June 26, 2026, that its Opzelura (ruxolitinib) cream received a positive CHMP opinion. The committee recommended the drug for adults with...
🟢 INCY extends move to 5.1% up
INCY is trading at $113.04, up 5.1% versus the comparison close of $107.53 during regular trading. This is a price-movement alert; no separate company-specific...
🟢 INCY is trading 6% up today following clinical updates and a favorable Medicaid settlement
INCY is trading 6% up at $113.97 following a series of positive clinical and regulatory developments alongside a broader sector rebound. • Key catalysts...
🟢 INCY is trading 4% up today as investors buy into its strong earnings and pipeline story
INCY is trading 4% up at $108.59 as investors continue to buy into its strong recent earnings and pipeline story despite concerns about a 2028 patent cliff. •...
Incyte Rallies Past $109 on Lingering Earnings Glow — But Can It Outrun the 2028 Patent Cliff?
Shares of Incyte Corporation climbed 4.4% in pre-market trading to $109.00 on June 24, extending a weeklong rebound from below $99 as investors continue to...
🟢 INCY is trading 4.4% up today on multiple positive catalysts including a Truist Securities price target raise
• Incyte is trading 4.4% up at $109.00 today, buoyed by several positive company-specific announcements. • Truist Securities raised its price target to $105.00...